Advisers to the US Food and Drug Administration voted Friday in favor of recommending the authorization for emergency use of a booster of the Pfizer vaccine in high-risk groups. That is, people 65 years of age and older, and those with a probability of suffering a severe disease as a result of covid-19. Dr. Elmer Huerta explains this decision, which still needs to complete its authorization process with the country’s health authorities.
Advisers to the US Food and Drug Administration voted Friday in favor of recommending the authorization for emergency use of a booster of the Pfizer vaccine in high-risk groups. That is, people 65 years of age and older, and those with a probability of suffering a severe disease as a result of covid-19. Dr. Elmer Huerta explains this decision, which still needs to complete its authorization process with the country’s health authorities.